In an article reviewing advancements in DNA plasmids, Eyevensys is featured with other innovative companies developing nonviral gene therapy.
Eyevensys presents data showing the efficacy and durability of EYS809, a dual-gene plasmid in development for the treatment of wet age-related macular degeneration (AMD).
The $12M raised in a Series B Plus funding round will support development of Eyevensys’s EYS809 program for the treatment of wet age-related macular degeneration (AMD), a chronic eye disorder that causes blurred vision or a blind spot in the eye.
Paris- and Cambridge, Mass.-based biotech company developing therapies for ophthalmic diseases raised $12 million in Series B+ funding, led by Korea Investment Partners.
A non-viral gene therapy sustained drug-delivery product that delivers anti-VEGF to the eye may replace the need for repeated intravitreal anti-VEGF injections and improve vision in patients with wet AMD.
LABIOTECH.eu reports on Eyevensys and other innovative companies developing gene therapy treatments with the potential to cure different forms of genetic blindness.
Eyevensys CEO, Patricia Zilliox, discusses innovation as a key component of growth in the medical and pharmaceutical industry, what her work has taught her about fundraising, and the impact of the pandemic on her work.
Watch Eyevensys Founder and Chief Innovation Officer, Prof. Francine Behar-Cohen, present at the OIS Ocular Drug Delivery Meeting, providing details about our innovative non-viral gene therapies for the treatment of ocular diseases and our active pipeline and strategy.
OIS Drug Delivery Innovation Showcase – Eyevensys from Healthegy on Vimeo.
Eyevensys founder, Francine Behar-Cohen, and Scientific Director, Thierry Bordet talk to Le Figaro about the company’s innovative treatments and technology in development for treating eye diseases. (article and video)
Listen to Patricia Zilliox, CEO of Eyevensys, discuss her background, her industry experience and expertise, and her passion for developing treatments to improve patient outcomes.
